Jeff Yass’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-109,860
| Closed | -$4.35M | – | 13534 |
|
|
2024
Q1 | $4.35M | Buy |
109,860
+87,085
| +382% | +$2.57M | ﹤0.01% | 3860 |
|
|
2023
Q4 | $434K | Buy |
+22,775
| New | +$316K | ﹤0.01% | 9012 |
|
|
2023
Q3 | – | Sell |
-11,451
| Closed | -$118K | – | 13262 |
|
|
2023
Q2 | $118K | Buy |
11,451
+817
| +8% | +$7.37K | ﹤0.01% | 10815 |
|
|
2023
Q1 | $82.1K | Sell |
10,634
-11,528
| -52% | -$91.8K | ﹤0.01% | 11421 |
|
|
2022
Q4 | $163K | Buy |
+22,162
| New | +$142K | ﹤0.01% | 10396 |
|
|
2022
Q3 | – | Sell |
-14,121
| Closed | -$120K | – | 14366 |
|
|
2022
Q2 | $120K | Buy |
14,121
+1,700
| +14% | +$14.7K | ﹤0.01% | 11283 |
|
|
2022
Q1 | $111K | Buy |
+12,421
| New | +$107K | ﹤0.01% | 11833 |
|
|
2021
Q2 | – | Sell |
-59,728
| Closed | -$633K | – | 13436 |
|
|
2021
Q1 | $633K | Buy |
+59,728
| New | +$745K | ﹤0.01% | 8919 |
|
|
2017
Q1 | – | Sell |
-3,646
| Closed | -$33K | – | 10196 |
|
|
2016
Q4 | $33K | Buy |
+3,646
| New | +$72.7K | ﹤0.01% | 9367 |
|
|
2015
Q4 | – | Sell |
-5,091
| Closed | -$264K | – | 10098 |
|
|
2015
Q3 | $264K | Buy |
+5,091
| New | +$334K | ﹤0.01% | 8244 |
|
Jeff Yass's ALPN Position: Q2 2024 in Review
Jeff Yass sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 109,860 shares — an estimated $4.35M sold.
Jeff Yass first reported a position in ALPN in Q3 2015 and held it in 10 quarters. The position peaked at $4.35M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Jeff Yass reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Jeff Yass sold 109,860 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $4.35M.
- Jeff Yass first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 10 quarters.
- Jeff Yass's Alpine Immune Sciences Inc position peaked at $4.35M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.